IL2 and renal cell carcinoma: However, in a phase III trial, combining the TroVAax (MVA-5T4) vaccine with either sunitinib, IL-2, or IFN-α in RCC patients did not enhance survival relative to sunitinib alone (or IL-2 or IFN-α alone) (Amato et al., 2010).